SCO - 088 is a novel and highly selective Bcr – Abl kinase inhibitor, intended for treatment resistant Chronic Myelogenous Leukemia (CML).

There are several drugs approved for the treatment of CML; however, patients stop responding to these treatments over a period of time. Currently, there are very limited treatment options for patients who have failed to two lines of treatment and especially if they have mutations like T315I.

SCO - 088 is a potent inhibitor of Bcr-Abl and its mutant forms.

SPARC successfully completed part A of the Phase 1 study in healthy volunteers in USA and have established oral bio-availability of the drug. PK data supports once-a-day dosing. Unlike most of the available TKIs that have reported cardiac side effects SCO - 088 was well tolerated and no serious adverse events were reported with SCO - 088 during part A of the study. 

 

Part B clinical study in patients has been completed with no serious cardio vascular events observed. Part C clinical study has been initiated

For more details on the ongoing study, visit: www.vodobatinib.com